Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • kyjellie kyjellie Aug 22, 2012 11:38 AM Flag

    Leukemia drug could take ASTX to $100

    Okay J Paul Getty. First of all, I don't care, second you have no idea of how many shares anyone has to make these claims.

    I just wonder, why would you invest in a company that you despise the CEO. Specially shares we only could only dream about.

    No, what you're willing to do is whine. The glass is always half empty with you mero. As for potential of sgi-110, that 5 years is now down to 2 years. I believe they have a shot at approval after ph2 for MDS. Slim, but not impossible.


    Looks like the man with greatest investment in ASTX, doesn't even have a sentiment disclosure. Must be that stack of shares he has is blocking the button. I love how the dingdongs always want to paint them selfs as major players. I think you and rory toy around in make believe word to much.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Kjelly dummy, you asked.

      The greatest fact is Supergen/ Astex has never, I say never successfully brought a drug to market successfully.

      The closest is Dacogen when MGI pharmas steps up and did what Supergen could not.

      If you look at Astex's drug candidates they are based on new technology. FDA approval is quite difficult if near impossible when new technology is introduced to the FDA.

      5 years to get to phase 1, no drug approval experience and you say approval after phase. 2. I say what drugs are you on?

      • 1 Reply to merohricht
      • Mero,

        "If you look at Astex's drug candidates they are based on new technology. FDA approval is quite difficult if near impossible when new technology is introduced to the FDA"

        What new technology are you thinking they are using? Please explain. I would like to hear this.

        As for sgi-110 getting approval after ph2. They actually could have skipped the ph1 and ph2 and used the 504B pathway for approval. Since sgi-110 is just another form of decitabine, I believe they can use all the data from previous trials for approval. They are not reinventing the wheel here. How many trials do you see where Survival is part of the trial?

        As for taking additional years to get in ph1, they made sure the delivery method was an improvement also. If you had read what I posted about side effects, you would have seen a tremedous improvement.

        Please enlighten us on how the Fed will not understand the technology. To show that you don't have a clue....SGI-110 is one of SUPG's drugs. Only rory is this dumb.

    • "Second you have no idea of how many shares anyone has to make these claims."

      One thing we do know. We all own more shares than the insiders.

 
ASTX
8.4950.0000(0.00%)Oct 10 4:00 PMEDT